TARS vs. VIR, NMRA, FDMT, CGEM, SRRK, BCRX, INBX, AUTL, CGON, and FUSN
Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Vir Biotechnology (VIR), Neumora Therapeutics (NMRA), 4D Molecular Therapeutics (FDMT), Cullinan Oncology (CGEM), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Inhibrx (INBX), Autolus Therapeutics (AUTL), CG Oncology (CGON), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "biological products, except diagnostic" industry.
Tarsus Pharmaceuticals (NASDAQ:TARS) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
Tarsus Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -677.69%. Vir Biotechnology's return on equity of -32.58% beat Tarsus Pharmaceuticals' return on equity.
In the previous week, Tarsus Pharmaceuticals had 10 more articles in the media than Vir Biotechnology. MarketBeat recorded 11 mentions for Tarsus Pharmaceuticals and 1 mentions for Vir Biotechnology. Tarsus Pharmaceuticals' average media sentiment score of 0.82 beat Vir Biotechnology's score of 0.40 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.
Tarsus Pharmaceuticals received 3 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 64.62% of users gave Tarsus Pharmaceuticals an outperform vote while only 48.15% of users gave Vir Biotechnology an outperform vote.
Tarsus Pharmaceuticals has higher earnings, but lower revenue than Vir Biotechnology. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Tarsus Pharmaceuticals presently has a consensus price target of $50.38, suggesting a potential upside of 32.57%. Vir Biotechnology has a consensus price target of $33.57, suggesting a potential upside of 245.74%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
Summary
Tarsus Pharmaceuticals beats Vir Biotechnology on 11 of the 18 factors compared between the two stocks.
Get Tarsus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tarsus Pharmaceuticals Competitors List
Related Companies and Tools
